Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Contineum Therapeutics, Inc. (CTNM) had Income from Continuous Operations of $-59.98M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-59.98M |
|
-- |
|
-- |
|
$68.06M |
|
$-68.06M |
|
$8.08M |
|
$-59.98M |
|
$-59.98M |
|
$-59.98M |
|
|
Income from Continuous Operations |
$-59.98M |
$-59.98M |
|
$-59.98M |
|
$-68.06M |
|
$-67.74M |
|
27.70M |
|
27.70M |
|
$-2.17 |
|
$-2.17 |
|
| Balance Sheet Financials | |
$267.92M |
|
$0.83M |
|
$8.72M |
|
$276.64M |
|
$9.74M |
|
-- |
|
$5.91M |
|
$15.65M |
|
$260.99M |
|
$260.99M |
|
$260.99M |
|
37.32M |
|
| Cash Flow Statement Financials | |
$-55.31M |
|
$-3.71M |
|
$112.69M |
|
$21.94M |
|
$75.60M |
|
$53.66M |
|
$10.04M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
27.50 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-55.54M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-22.98% |
|
-22.98% |
|
-21.68% |
|
-22.98% |
|
$6.99 |
|
$-2.01 |
|
$-2.00 |
|